Trials / Completed
CompletedNCT02313922
Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate
Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate: a Phase IV, Multicenter, Randomized, Double-blind, Controlled Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 466 (actual)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate whether etanercept combined with methotrexate are superiority than etanercept as monotherapy in the treatment of chinese severe plaque psoriasis. A phase IV, multicenter, randomized, double-blind, controlled trial was conducted.The primary outcome was Change from baseline in plaque psoriasis as assessed by PASI (psoriasis area and severity index) response or PASI75 (a patient that has an improvement from baseline PASI of at least 75%)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | etanercept combined with methotrexate or etanercept combined with placebo |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2018-08-01
- Completion
- 2018-08-01
- First posted
- 2014-12-10
- Last updated
- 2018-08-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02313922. Inclusion in this directory is not an endorsement.